Cargando…

3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease

BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Knubel, Carolina P., Martínez, Fernando F., Acosta Rodríguez, Eva V., Altamirano, Andrés, Rivarola, Héctor W., Diaz Luján, Cintia, Fretes, Ricardo E., Cervi, Laura, Motrán, Claudia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197528/
https://www.ncbi.nlm.nih.gov/pubmed/22028903
http://dx.doi.org/10.1371/journal.pone.0026550
_version_ 1782214320273227776
author Knubel, Carolina P.
Martínez, Fernando F.
Acosta Rodríguez, Eva V.
Altamirano, Andrés
Rivarola, Héctor W.
Diaz Luján, Cintia
Fretes, Ricardo E.
Cervi, Laura
Motrán, Claudia C.
author_facet Knubel, Carolina P.
Martínez, Fernando F.
Acosta Rodríguez, Eva V.
Altamirano, Andrés
Rivarola, Héctor W.
Diaz Luján, Cintia
Fretes, Ricardo E.
Cervi, Laura
Motrán, Claudia C.
author_sort Knubel, Carolina P.
collection PubMed
description BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the known proapoptotic and immunoregulatory properties of 3-HK and their downstream catabolites, it is possible that the 3-HK treatment is effective during the acute phase of the infection by controlling the parasite replication, but at the same time suppressed the protective T cell response before pathogen clearance worsening the chronic phase of the infection. Therefore, in the present study, we investigated the effect of 3-HK treatment on the development of chronic Chagas’ disease. PRINCIPAL FINDINGS: In the present study, we treated mice infected with T. cruzi with 3-HK at day five post infection during 5 consecutive days and investigated the effect of this treatment on the development of chronic Chagas disease. Cardiac functional (electrocardiogram) and histopathological studies were done at 60 dpi. 3-HK treatment markedly reduced the incidence and the severity of the electrocardiogram alterations and the inflammatory infiltrates and fibrosis in heart and skeletal muscle. 3-HK treatment modulated the immune response at the acute phase of the infection impairing the Th1- and Th2-type specific response and inducing TGF-β-secreting cells promoting the emergence of regulatory T cells and long-term specific IFN-γ secreting cells. 3-HK in vitro induced regulatory phenotype in T cells from T. cruzi acutely infected mice. CONCLUSIONS: Our results show that the early 3-HK treatment was effective in reducing the cardiac lesions as well as altering the pattern of the immune response in experimental Chagas’ disease. Thus, we propose 3-HK as a novel therapeutic treatment able to control both the parasite replication and the inflammatory response.
format Online
Article
Text
id pubmed-3197528
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31975282011-10-25 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease Knubel, Carolina P. Martínez, Fernando F. Acosta Rodríguez, Eva V. Altamirano, Andrés Rivarola, Héctor W. Diaz Luján, Cintia Fretes, Ricardo E. Cervi, Laura Motrán, Claudia C. PLoS One Research Article BACKGROUND: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the known proapoptotic and immunoregulatory properties of 3-HK and their downstream catabolites, it is possible that the 3-HK treatment is effective during the acute phase of the infection by controlling the parasite replication, but at the same time suppressed the protective T cell response before pathogen clearance worsening the chronic phase of the infection. Therefore, in the present study, we investigated the effect of 3-HK treatment on the development of chronic Chagas’ disease. PRINCIPAL FINDINGS: In the present study, we treated mice infected with T. cruzi with 3-HK at day five post infection during 5 consecutive days and investigated the effect of this treatment on the development of chronic Chagas disease. Cardiac functional (electrocardiogram) and histopathological studies were done at 60 dpi. 3-HK treatment markedly reduced the incidence and the severity of the electrocardiogram alterations and the inflammatory infiltrates and fibrosis in heart and skeletal muscle. 3-HK treatment modulated the immune response at the acute phase of the infection impairing the Th1- and Th2-type specific response and inducing TGF-β-secreting cells promoting the emergence of regulatory T cells and long-term specific IFN-γ secreting cells. 3-HK in vitro induced regulatory phenotype in T cells from T. cruzi acutely infected mice. CONCLUSIONS: Our results show that the early 3-HK treatment was effective in reducing the cardiac lesions as well as altering the pattern of the immune response in experimental Chagas’ disease. Thus, we propose 3-HK as a novel therapeutic treatment able to control both the parasite replication and the inflammatory response. Public Library of Science 2011-10-19 /pmc/articles/PMC3197528/ /pubmed/22028903 http://dx.doi.org/10.1371/journal.pone.0026550 Text en Knubel et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Knubel, Carolina P.
Martínez, Fernando F.
Acosta Rodríguez, Eva V.
Altamirano, Andrés
Rivarola, Héctor W.
Diaz Luján, Cintia
Fretes, Ricardo E.
Cervi, Laura
Motrán, Claudia C.
3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title_full 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title_fullStr 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title_full_unstemmed 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title_short 3-Hydroxy Kynurenine Treatment Controls T. cruzi Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease
title_sort 3-hydroxy kynurenine treatment controls t. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic chagas disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197528/
https://www.ncbi.nlm.nih.gov/pubmed/22028903
http://dx.doi.org/10.1371/journal.pone.0026550
work_keys_str_mv AT knubelcarolinap 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT martinezfernandof 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT acostarodriguezevav 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT altamiranoandres 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT rivarolahectorw 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT diazlujancintia 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT fretesricardoe 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT cervilaura 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease
AT motranclaudiac 3hydroxykynureninetreatmentcontrolstcruzireplicationandtheinflammatorypathologypreventingtheclinicalsymptomsofchronicchagasdisease